Last updated on January 2019

Study of Durvalumab + Tremelimumab Durvalumab and Placebo in Stage I-III Limited Disease Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy


Brief description of study

This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III LD-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Clinical Study Identifier: NCT03703297

Contact Investigators or Research Sites near you

Start Over

Research Site

Ostrava, Czechia
1.29miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.